A vast number of diseases could be treated with therapeutic cells derived from pluripotent stem cells (PSCs). However, cell products that come from non-autologous sources can be immune rejected by the recipient's immune system. Here, we show that forced expression of eight immunomodulatory transgenes, including Ccl21, Pdl1, Fasl, Serpinb9, H2-M3, Cd47, Cd200, and Mfge8, allows mouse embryonic stem cells (mESCs) and their derivatives to escape immune rejection in fully immunocompetent, allogeneic recipients. Despite no genetic alterations to major histocompatibility complex (MHC) genes, immune-modified C57BL/6 mESCs could generate long-term, allogeneic tissues in inbred FVB/N, C3H, and BALB/c, as well as outbred CD-1 recipients. Due to the tandem incorporation of our safe-cell suicide system, which allows tight and drug-inducible control over proliferation in vivo, these allotolerated cells can generate safe and dormant ectopic tissues in the host. We show that these ectopic tissues maintain high expression of all eight immunomodulatory transgenes and are immune-privileged sites that can host and protect unmodified mouse and human cells from rejection in allogeneic and xenogeneic settings, respectively. If translated to human clinical settings, we envision the development of a single pluripotent cell line that can be used to generate allo-tolerated, off-the-shelf cell products to serve all humankind, as well as immuneprivileged ectopic tissues to host and immune-protect any kind of therapeutic cell product.
INTRODUCTION
Immune rejection of allogeneic cells remains a major barrier to the clinical advancement of cell-base therapies. While induced pluripotent stem cells (iPSCs) could be used to generate personalized therapies, routine generation of patient-specific iPSCs in the clinic is unrealistic given the costs and regulatory compliance required. Furthermore, this approach would exclude patients in need of immediate treatment with acute diseases or injuries. Cell banks of PSCs lines selected for the most common human leukocyte antigen (HLA) haplotypes have been suggested as a solution 1 . However, these would fail to serve uncommon haplotypes and still contain differences in minor histocompatibility antigens. While current regiments of immunosuppressive drugs support acceptance of allogeneic cells, systemic immune suppression often leads to lifethreatening malignancies and infections.
A potential solution involves the immune modification of PSCs such that their therapeutic derivatives are no longer recognized or attacked by the immune system in allogeneic recipients.
A recent report showed that replacement of HLA class I in human PSCs with the inhibitory HLA-E prevented NK and CD8 T-cell responses in vitro as well clearance after engraftment into humanized mouse models 2 . Others have combined deletion of MHC class I and II with the forced expression of one or more immunosuppressive transgenes 3, 4 . While promising, MHC-modified or null cells still express minor antigens and other gene polymorphisms that can become targets of rejection and humoral immunity over time [5] [6] [7] . Also, cells without MHC/HLA class I or II genes would be unable present viral or bacterial peptides during infection.
We sought to engineer PSCs in a way that accounted for both the major and minor antigens, did not involved deletion of MHC class I/II genes, and which allowed for long-term acceptance in a variety of recipient genetic backgrounds. We were encouraged by prototypical examples of immune escape in nature, such as the devil facial tumour disease (DFTD) type 2, a horizontally-transmitted cancer in Tasmanian Devils [8] [9] [10] . Here, we show that the forced expression of eight immunomodulatory transgenes alone in mouse embryonic stem cells (mESCs), without deletion of MHC genes, is sufficient to protect their cell derivatives long-term from rejection in many immunocompetent and allogeneic recipient strains. The use of immunomodulatory factors that interfere with the activity of several immune cell types, including T-cells, NK-cells, antigen presenting cells, and macrophages, was rationalized based on the known complexity of allogeneic immune responses, which may not be reflected in short-term and/or humanized mouse models of allo-transplantation.
Cells that evade immunity system are inherently risky, since the immune system may not be able to clear them should a malignancy arise. Thus, the allo-tolerated ESCs generated here also contain our recently developed safe-cell system 11 . This system consists of a kill-switch genomically-integrated into a gene essential for cell division, providing a unique level of safety for the allo-tolerated cells. It also allows for the generation of a stable, ectopic tissue that can be derived from safe-cell ESCs when the safe-cell system is activated after engraftment in vivo. We show that when an ectopic tissue is generated from allo-tolerated mESCs, it becomes a locallyimmune-privileged site that can host and protect wild-type allogeneic mouse and xenogeneic human cells from rejection in fully immunocompetent recipient strains.
RESULTS

Selection of immunomodulatory genes to disrupt allogeneic immune rejection
To target dendritic cells ( Fig. 1a) , we selected the gene Ccl21 encoding a chemokine expressed in the lymph nodes that recruits activated dendritic cells to prime adaptive immunity 12 .
Some cancers express CCL21 13 , which may disrupt the ability of local dendritic cells to emigrate out and activate adaptive immunity. To target T-and NK-cells, we selected Pdl1, Fasl, H2-M3, ands Serpinb9 (Fig 1b) . PDL1 is a well-described checkpoint inhibitor and can shut down effector T-cells 14 , while FASL can induce T-cell aptopsis 15 . H2-M3 is a non-classical MHC molecule that can inhibit NK cells 16 , while SERPINB9 blocks the apoptosis-inducing Granzyme B released from activated NK and T-cells 17 . To target monocytes and macrophages, we selected Cd47, Cd200, and Mfge8 (Fig 1c) . CD47 and CD200 inhibits release of inflammatory cytokines and phagocytosis by macrophages 18, 19 , while MFG-E8 can similarly skew macrophages towards an anti-inflammatory profile during macrophage phagocytosis and contact with dying cells 20 .
Expression of immunomodulatory transgenes in safe-cell mESCs
The cDNA of the genes encoding these factors were individually cloned into piggyBac [21] [22] [23] and Sleeping Beauty 24, 25 transposon-based expression vectors in which transcription was driven by the strong synthetic CAG promoter 26 and linked to a drug-selectable (Puromycin or Neomycin) marker or fluorescent (eGFP) reporter by an internal ribosomal entry site (IRES) ( Fig. 2a and Supplementary Fig. 1Sa ). All eight immunomodulatory transgenes, as well as a transgene encoding enhanced luciferase to allow in vivo tracking by Bioluminescent Imaging (BLI), were transfected into mouse safe-cell C57BL/6 mESCs. The safe-cell mESC parental line is a recentlydeveloped clonal derivative of a C57BL/6 mESC line 27 that contains a thymidine kinase (TK) suicide gene transcriptionally linked to the cell division essential, endogenous Cdk1 gene 11 . Any dividing cell that co-expresses CDK1 and TK can be killed by activating the TK protein with the pro-drug ganciclovir (GCV).
Using the piggyBac and Sleeping Beauty transposon system coupled with in vitro drug selection and flow cytometry cell sorting, we isolated polyclonal pools of cells with high expression levels of each immunomodulatory transgene (described in Supplementary Fig. 1b ).
From these polyclonal pools, we then established 47 single cell-derived clonal lines and quantified the expression level of each transgene by qRT-PCR ( Fig. 2b) . Expression of the protein encoded by each transgene was confirmed with immunohistochemistry on selected clones in vitro (Fig. 2c ). These factors were undetectable in parental safe-cell mESCs, with the exception of MFG-E8 and SERPINB9, which is consistent with our qRT-PCR results or previously-published results 28, 29 .
Long-term acceptance of immune-modified C57BL/6 mESCs and their derivatives in allogeneic recipients
From the 47 immune-modified, transgene-containing safe-cell mESC lines, we selected 13 candidate lines with varying overall transgene expression levels, chosen by qualitative assessment of the qPCR radial graphs (Fig. 2b) , and used BLI to examine short-term survival in immunocompetent isogenic and allogeneic recipients. As expected, non-immune-modified C57BL/6 (H-2k b ) safe-cell mESCs survived in isogenic recipients ( Fig. 3a , top row, Fig. 3d ,e) but were quickly cleared from allogeneic FVB (H-2k q ), C3H (H-2k k ), and outbred CD-1 mice within 5-10 days after subcutaneous injection ( Fig. 3a ). However, some of the generated clones -one hereafter named Klg-1 (shown as "Clone 1" in Fig. 2b ) -could still be detected in allogeneic FVB recipients at least 17 days after injection (Fig. 3b ). Encouraged by these results, we then tested if Klg-1 mESCs could form teratomas in allogeneic recipients ( Fig. 3c ). Indeed, Klg-1 mESCs formed well-vascularized teratomas in all allogeneic backgrounds tested, including FVB/N, C3H, BALB/c and CD-1 ( Fig. 3d,e ). Within two months after transplantation, the mESC-derived teratomas reached a size that required euthanasia of the recipient (Fig. 3d , top graph), which would typically limit the length of such a survival study. So, to test if the Klg-1-derived, allotolerated tissues could survive long-term, we activated the TK-based safe-cell system with the administration of GCV to recipients when the tissues reached an approximate size of 400-500 mm 3 . 14-21 days of treatment with GCV kills all proliferating cells and stabilizes the teratoma tissue indefinitely 11 . We were able to generate long-term and safe-cell-activated Klg-1-derived teratomas in more than 100 allogeneic recipients among all genetic backgrounds tested ( Fig.   3d ,e). Strikingly, we did not observe a single instance of clearance once these tissues had formed, including mice that were monitored for up to 9 months after transplantation. A complete list of all tested mice and the observation period is shown in Supplementary Table S1. In addition to clone Klg-1, we isolated a second immune-modified clone, termed Klg-2 (shown as "Clone 43" in Fig. 2b ), that could also form long-term and GCV-stabilized teratomas in allogeneic recipients, albeit with varying efficiency compared to Klg-1, and which was only tested in FVB and C3H strains ( Supplementary Fig. 2 ).
Isogenic and allogeneic Klg-1 mESCs teratomas formed cell types of all three embryonic germ layers, including endoderm, mesoderm, and ectoderm ( Fig. 4a ), indicating that the forced expression of the eight immunomodulatory transgenes did not alter the gross pluripotent developmental potential of the parental cell line. As expected based on their long-term survival, these teratomas were well-vascularized (Fig. 4b ). The differentiated cells contained in the GCV-stabilized teratomas expressed high levels of MHC class I molecules, comparable to teratomas derived from non-immune-modified parental safe-cell mESCs in isogenic recipients (Fig. 4c ). The robust expression of class I on teratomas demonstrates that the allo-protective effect of the eight immunomodulatory transgenes remains efficient accross MHC differences and can not be attributed to downregulation of MHC.
To quantify and better understand the expression level of each immunomodulatory transgene in reference to the rest of the genome, we then performed next-generation sequencing (NGS) on RNA isolated from in vitro-cultured parental safe-cell and Klg-1 mESCs , as well as cells from long-term accepted Klg-1 tissue formed in allogeneic FVB recipients. As expected, the immunomodulatory transgenes were expressed at high levels in Klg-1 mESCs compared to parental safe-cell mESCs, and this high level of expression was preserved in teratomas formed by Klg-1, despite the random cell differentiation that occurs during teratoma development ( Fig. 4d ). In fact, placed against all the endogenous genes of the genome, the immunomodulatory transgenes in both cultures (Klg-1 mESCs and allogeneic Klg-1 teratomas) were among the highest 5% expressed, with several of the transgenes among the highest 1%.
This data fits with the fact that, among the 13 immune-modified mESCs clones tested in vivo with a range of overall transgene expression levels, those with the overall highest level of expression (Clone 1 and 43, Fig. 2b ) were those that could be allo-tolerated.
We then performed splinkerette PCR on genomic DNA from Klg-1 mESCs using primers against the transposon inverse terminal repeats and sequenced the products by NGS. By comparing the amplified sequence of the products to a reference mouse genome 30, 31 , we identified 56 genomic insertion sites of piggyBac-flanked transgenes into Klg-1 mESCs ( Supplementary Table S2 ). Of these insertions, one was in an exon (Hells), one in the 3'UTR (Fasl), and one in the 5'UTR (Anapc11) of a gene. We found that eight intronic insertions and the rest (45) were intergenic.
Allo-tolerated safe-cell mESCs can generate clinically-relevant cell types in vitro
We next examined the in vitro properties of Klg-1 mESCs. As expected based on their pluripotency in vivo, Klg-1 mESCs had typical ESC colony morphology ( Fig. 5a ), could form embryoid bodies (Fig. 5b) , and expressed the ESC markers OCT4 and SSEA1 (Fig. 5c ). In spontaneously-differentiated Klg-1 embryoid bodies, both neuronal and muscle cells could be identified. Using directed protocols, Klg-1 could be differentiated into cardiomyocytes ( Fig. 5c , Supplementary Fig. 3 , and Supplementary Movie S1,2), CD31+ cells, and Fox2A+Sox17+ cells of the definitive endoderm lineage (Fig. 5c ). Together, these data show that forced expression of these eight immunomodulatory factors did not affect Klg-1 mESC pluripotency or the ability to form potentially therapeutic cell types in vitro.
Ectopic tissues formed by allo-tolerated mESCs serve as an immune-privileged site that can protect wild type allogeneic mouse and xenogeneic human cells
The high level of transgene expression detected at the RNA level in the teratoma ( Fig. 4d) was also reflected at their encoded protein levels ( Fig. 6a ). Based on this observation, we next asked if allogeneic teratomas could host and protect non-immune-modified safe-cells from rejection in allogeneic hosts. First, Klg-1 teratomas were generated in FVB recipients and stabilized by GCV treatment for 40 days (Fig. 6b ). Then, allogeneic, non-immune-modified, luciferase+ safe-cell mESCs were injected directly into the teratoma and their presence followed for 40 days by BLI. Injected safe-cell mESCs survived inside the FVB-hosted Klg-1 teratomas and continued to proliferate such that the recipients required an additional round of GCV to stabilize the growth of the injected cells. To show that the survival of allogeneic safe-cell mESCs resulted from the immune-privileged nature of the Klg-1 teratoma, the same safe-cell mESCs were then injected subcutaneously into the contralateral flank of the same FVB recipients. While these subcutaneously-injected mESCs could be detected 5 days later, they were later cleared with no signal detected by 30 days. However, the prior safe-cell mESCs cells injected to the Klg-1 teratoma persisted even while the same safe-cell mESC line was rejected from the contralateral flank.
We then extended these experiments to a xenogeneic transplant model utilizing our safecell human ESC line (hESC luc+ ) 11 . These cells expand and can form GCV-stabilized tissues when injected subcutaneously into immune compromised (Nod-SCID-Gamma, NSG) mice, and can be tracked by BLI ( Supplementary Fig. 4 ). After establishing GCV-stabilized safe-cell or Klg-1 teratomas in isogenic recipients, hESC luc+ cells were injected into the teratomas and tracked by BLI for several months. When injected into safe-cell teratomas, hESC luc+ cells were cleared within 20 days, but those injected into Klg-1 teratomas persisted long-term without rejection ( Fig. 6c ).
These results show that cells expressing the eight immunomodulatory genes are not only allotolerated in a allogeneic setting, but can also form an immune-privileged tissue to protect embedded wild type allogeneic and even xenogeneic cells.
DISCUSSION
We show here that the forced expression of eight immunomodulatory factors in cells is sufficient to escape immune rejection in allogeneic hosts. Other attempts to engineer allotolerated cells have focused on removing MHC genes and/or the introduction of just one or a few factors [2] [3] [4] 32 . The emphasis on MHC genes is clearly justified since they are the primary source of allogenic antigens during transplantation and loss of these molecules is often coincident with immune evasion in nature 33 . However, minor antigens, such as those derived from the Ychromosome or amino acids variations among common proteins can also become targets of immunity, especially during chronic rejection and development of anti-graft antibodies 6, 7, 34 .
Removing MHC genes involved in antigen presentation also carry risks, such as the inability to present viral and bacterial peptides should the cells become infected. Escape strategies that rely primarily on deletion of MHC gene also pose the additional risk that they cannot be reversed in vivo. The approach here, which relies solely on the use of overexpression of immunomodulatory factors, could be designed into inducible expression systems, such as the TetOFF system, so that transgene expression could be turned off if the transplanted cells become malignant or are no longer needed for a therapeutic effect. This would provide an additional dimension of safety in addition to the use of cell suicide systems.
Our multifactorial transgene approach stems from the premise that immune escape is necessarily difficult due to the highly adaptive and redundant nature of the mammalian immune system, which evolved in an arms race with malignancies, viruses, bacteria, and helminths. In fact, most examples of immune escape in nature require many loss or gain-of-function adaptations. This includes those where MHC expression is retained, including some transmissible cancers 9, 10 , as well as the placenta which expresses HLA-C 35 . The immune modulatory factors used in our study interfere with many key immune pathways, including antigen presentation and the generation of adaptive immunity, NK and T-cell-mediated lysis, and macrophage phagocytosis and general inflammatory responses. These cells and pathways are highly crossregulated, and targeting them simultaneously may support mutually-reinforcing effects. This is likely an important property of cells that can escape innate, cellular, and humoral immunity over long-term time scales.
The allo-tolerated mESC were generated following modest in vitro and in vivo screening methods. The necessity of very high expression levels of immunomodulatory transgenes in mESCs and teratomas could serve as a guideline in developing future allo-tolerated cells by similar methods in different species, including human. It emphasizes the importance of strong promoter elements and suitable transgene delivery methods to reduce the amount of in vitro and in vivo screening needed to identify allo-tolerated lines. In this study, we used a piggyBac and Sleeping Beauty transposon-mediated transgenesis. Under the proper conditions, we found transposon integration to be so efficient that co-transfection with multiple transgenes resulted in several genomic integration sites of each transgene. These multiple integrations resulted in a high level of expression and mitigated the site-specific silencing and expression variegation that can occur upon differentiation. Random transgene integration does, however, carry the risks of disrupting or activating endogenous genes that could lead to malignancies. It is also true that that the modifications required to generate universally, allo-tolerated cells are inherently dangerous because they can compromise the immune system's ability to survey and eliminate infected or potentially tumorigenic cells. For both these reasons, it is critical that the cells contain tightly-controlled cell safety systems, such as the one recently published by our group 11 , which was used here. This system consists of an HSV-TK suicide gene integrated into a locus required for cell division and allows reliable removal of dysregulated, dividing cells of graft origin. If needed, both the suicide gene and targeted endogenous gene could be varied to create other types of safe-cell systems, such as one capable of removing all grafted cells regardless of proliferative status, for example. Additionally, our safe-cell system allows for a mathematical quantification of risk 11 , which will be required for patients and clinicians to decide the risk-tobenefit ratio of future cell-based therapies, especially those derived from universal cell products.
In addition to allowing engraftment across MHC barriers, the presented approach to achieve allotolerance has an additional, unique property. Combined with the safe-cell system, it allowed us to create an immune-privileged tissue that protects not only wild type allogeneic mouse cells but also xenogeneic human cells. After activation of the safe-cell system by GCV treatment of the recipient, the allo-tolerated mESC-derived ectopic tissue is completely stable, dormant, and wellvascularized. Such an "artificial" immune-privileged site could have significant novel therapeutic potential. For example, it could provide a protective site to engraft wild type tissues or organoids that could treat endocrine disease or other factor deficiencies.
The data presented here are the first to demonstrate long-term survival of a solid tissue allograft in fully immune-competent hosts without the need for systemic immunosuppression.
These cells' ability to be allo-tolerated across MHC differences could be the reason behind their status as an immune-privileged tissue. Furthermore, if translated to a human setting our approach satisfies the need for a single pluripotent cell source, which could serve all humankind with safe, off-the-shelf therapeutic cell products and eliminate the need for patients to undergo systemic immune suppression. a. Schema of piggyBac (pB) and Sleeping Beauty (SB)-transposable plasmid used to express immunomodulatory factors in mESCs. cDNA encoding Ccl21, Pdl1, Fasl, Serpinb9, H2-M3, Cd47, Cd200, and Mfge8 were each cloned into separate pB and SB transposon vectors and integrated into the genome of safe-cell C57BL/6 mESCs 11 by transposition in sequential transfection and selection (as described in Supplementary Fig. 1 ). From the polyclonal transgenic pools, 47 clonal lines were isolated and expanded b. Expression levels of immunomodulatory transgenes in the clonal lines as measured by RT-qPCR. Each colored wedge shows the value of a specific transgene. All values relative to the expression in isolated splenocytes from C57BL/6 mice (control, thick black circle in each radial graph) activated ex vivo with antibodies against CD3 and CD28. Concentric circles; log10 scale. Non-immune modified safe-cell mESCs (parental line) shown in upper left box. Clones outlined in red and blue boxes were later screened in vivo for acceptance or rejection in allogeneic hosts (Fig 3) . Red boxes; clones accepted in allogeneic hosts (clone 1 and clone 43 renamed Klg-1 and Klg-2, respectively). Blue boxes; clones rejected in allogeneic hosts. c. Expression of transgene-encoded factors in Clone 1 (Klg-1) mESCs.
Fig. 3 | mESCs expressing eight immunomodulatory factors escape immune rejection and survive long-
term in multiple MHC-mismatched, immunocompetent strains. a. Non-immune modified luciferase+ C57BL/6 safe-cell mESCs were injected subcutaneously into isogenic (C57BL/6) or allogeneic (FVB, C3H, or CD-1) recipients and followed for 15 days with BLI. b. Klg-1 mESCs could still be detected in allogeneic (FVB) recipients 17 days after transplantation by BLI. c-e. Long-term acceptance of Klg-1 mESCs in isogenic and allogeneic mice. The recipients were monitored for the appearance of teratomas. When the expanding graft reached 500mm 3 , GCV was administered to recipients for several weeks to activate the safe-cell system and ablate dividing cells. Once stabilized, teratomas were monitored for long-term persistence. c. schema of long-term acceptance teratoma assay. d. Growth and survival curves of untreated and GCV-stabilized teratomas derived from safe-cell and Klg-1 mESCs in isogenic (C57BL/6) and allogeneic (FVB, C3H, BALB/c, and CD-1) recipients. Teratoma growth curves in 3-4 recipients shown per group. Pictures of teratomas (red arrows) shown from two mice per group. e. Percent of isogenic and allogeneic recipients that formed long-term and GCV-stabilized teratomas from transplanted safe-cell and Klg-1 safe-cell mESCs. Number in each horizontal bar indicates total number of mice that formed teratomas divided by total number of mice injected. Observation period ranged from 2 to 9 months depending on when recipients were euthanized. No instances of Klg-1 teratoma clearance occurred in any recipient. Data for all mice, including observation period, shown in Supplementary table S1. Supplementary Fig. S4 and Supplementary movie S1,2.
Fig. 6 | Ectopic subcutaneous tissues formed from allo-tolerated mESCs serve as an immune-privileged site that can protect allogeneic mouse and xenogeneic human cells from rejection. a.
Antibody staining of immunomodulatory factor in long-term safe-cell and Klg-1-derived teratomas in isogeneic and allogeneic recipients. b. Klg-1-derived teratomas protect parental safe-cell mESCs from rejection in allogeneic recipients. Klg-1 teratomas were established and stabilized with GCV over 40 days. 5x10 6 safe-cell mESCs were then injected into the teratoma and followed with BLI for 40 days (day 10-40).
Expansion of safe-cell mESCs within in Klg1 teratoma were halted by GCV treatment. Day-35 image verifies absence of signal detected from Klg-1-derived teratomas using 10 sec exposure time. At day 60, 5x10 6 safe-cell mESCs were injected subcutaneously into the contralateral (left) flank (red dotted boxes) and followed for 30 days with BLI. BLI images for day 60-90 are composite of two images, each side of the mouse taken at different exposures to account for varying signal intensities (right side; 10 seconds, left side; 1 min). c. Klg-1-derived teratomas protect luciferase+ human safe-cell ESCs (hESCs) from rejection in xenogeneic recipients. Stabilized safe-cell or Klg-1 mESC-derived teratomas were established and stabilized with GCV in isogenic C57BL/6 recipients. Then, 10-12 million luciferase+ safe-cell hESCs were injected into the teratoma and followed for 62 days with BLI. Images show one representative mouse, and BLI photon emission of all mice shown graphically (one safe-cell teratoma-injected recipient died from unrelated causes after 27). Red dotted boxes show region containing the teratoma and hESCs. Black dotted line shows detection limit. BLI exposure time;1 min.
MATERIALS AND METHODS
Mice. C57BL/6N (Stock No 005304), C3H/HeJ (Stock 000659), FVB/NJ (stock 001800), and BALB/c (Stock 000651) were purchased from Jackson Laboratory. CD1 (ICR) mice were purchased from Charles River. 6-10 week-old mice of each strain or background were used in teratoma assay.
Mice were housed in a pathogen-free facility at the Toronto Centre for Phenogenomics (TCP). Supplementary Table S3 . The cDNAs were cloned into piggyBac (pB) [21] [22] [23] and Sleeping Beauty(SB) 24, 25 transposon expression vectors transposon expression vectors} using the Gateway cloning kit (Thermo Fisher 12535029) per manufacturers protocol. Representative plasmid show in Fig. 2a and Supplementary Fig. 1a . Briefly, Pdl1, Cd47, H2-M3, Mfge8, Ccl21, and Cd200 were amplified by extension PCR using PrimeStar HS mastermix (Takara R040) and gateway compatible attb1/attb2 sites were added to the 5'end and 3' ends, respectively. All primers used for gateway cloning listed in Supplementary Table S3 . The plasmids containing Ccl21 and Serpinb9 cDNA contained cDNA-flanking attb1/attb2 sites and did not require extension PCR. All PCR-amplified transgenes were then recombined into the gateway pDONr221 vector (Thermo Fisher 12536017), and the transgene insertion was sequenced in the resulting entry vector using flanking M13 Forward and M13 Reverse, as well as transgene-specific primers listed in Supplementary Table S4 confluency. An episomal plasmid encoding hyperactive PBase (hyPBase) (The Sanger Center, pCMV-hyPBase) or sleeping beauty transposase was included when mESCs were transfected with piggyBac and Sleeping Beauty plasmids. After transfection, transgene-containing clones were generated using combinations of single cell sorting, drug selection with 150 ug/mL G418 (Invitrogen 10131035) or 1ug/mL Puromycin (Gibco A11138-03), bulk sorting using antibody staining against transgene encoded factors, and in vitro culture plating at clonal densities (200 cells per 100mm dish). The transfection sequence, sorting, and drug selection that led to transgene-containing clones is described in Supplementary Fig. S1 . For the drug selection steps, G418 or Puromycin was added to the selection media 24 hours after transfection and maintained until the appearance of antibiotic-resistant cells. All final transgene-containing clones were grown in triplicate 96-well plates for cryopreservation and DNA/RNA extraction.
qRT-PCR of immunodulatory transgenes. RNA was isolated from clonal cultures by removing the media and adding Trizol (Invitrogen 15593-031) for 5 minutes at room temperatures, followed by 150uL Chloroform (Sigma). After briefly vortexting and centrifugation at high speed, the nucleic acid phase was collected, precipitated with 100% iso-propanol, washed with 70% ethanol, and eluted in RNAse free water. cDNA was then made from isolated RNA with the QuantiTect Reverse Transcription Kit (Qiagen 205310). qPCR was performed using the SensiFast SYBR No-Rox Kit (Frogga Bio BIO-98020) per manufacturer's protocol on a Bio-Rad C1000 CFX384.
The forward and reverse primers used to detect inserted transgenes designed to span only exons to avoid detection of endogenous genes. Transgene expression levels were compared to levels of activated splenocytes, and everything normalized to primers against Eef2. All primer sequences listed in Supplementary Table S5 . 36 . Trimmed paired reads were then aligned with the end-to-end mode of STAR tool 39 and visualized in IGV 40, 41 . High quality reads were then filtered for only those beginning or ending with TTAA (the sequences at which piggyBac inserts into the genome 23 ) and
overlapping with the nearest read by a TTAA sequence. 93 candidate regions of insertion were identified, and then filtered to sort on only those where paired reads were present on both sides of the TTAA region and without a TTAA in the middle of the read, ultimately resulting in 56 high quality candidates, listed in Supplementary Table S2 . Teratoma size was measured with calipers and the volume calculated using the formula V = (LxWxH)π/6. At endpoint, mice were euthanized and the teratomas excised for immunohistochemistry and histology.
Stabilization of teratomas with Ganciclovir (GCV)
. All mESCs used in these studies contain the safe-cell system which contains a thymidine kinase suicide gene targeted to the CDK1 locus 11 .
Therefore, for long-term acceptance studies, mice with mESCs-derived teratomas were given Ganciclovir (Cytovene) once teratomas reached an approximate volume of 400-500mm 3 for a period of several weeks, depending on the strain. Any mice in which teratoma growth resumed at a later date after GCV withdrawal was given GCV again for several days. Ganciclovir administration was given as daily intraperitoneal injections at a dose of 50mg/kg in 100uL PBS. 
